IP Library › Granted Patent US 8,633,245
Granted Patent B2
US 8,633,245 · App. 12/422,099 · Granted Jan 21, 2014

PAI-1 inhibitor

Inventors: Youichi Yamaguchi (Tokyo, JP); Takeshi Yanase (Tokyo, JP); Susumu Muto (Tokyo, JP); Akiko Itai (Tokyo, JP)
Assignee: Institute of Medicinal Molecular Design, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,633,245
App. No.
12/422,099
Granted
Jan 21, 2014
Kind
B2
Abstract

The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; wherein: R 1 represents a C 6-10 aryl group which may be substituted or the like; T represents a single bond or the like; m represents 0 or 1; when m is 0, G represents —N—C(═O)—CO 2 H or the like; when m is 1, G represents an oxygen atom or the like; R 2 represents a C 6-10 aryl group which may be substituted or the like; E represents the following formula (II) wherein one of R 31 , R 32 , R 33 and R 34 represents the formula R 1 -T-, each of the other three independently represents a hydrogen atom or the like, and R 35 represents the formula —X—Y′, a hydrogen atom or the like; X represents —CH 2 — or the like; Y′ represents a carboxy group or the like; M represents a single bond or the like.

Claims (41)

1. A compound represented by the following formula (I) or a salt thereof:

wherein:

m represents 1;

E represents the following formula (II):

wherein

R 35 represents the formula —X—Y′; and

one of R 31 , R 32 , R 33 and R 34 represents the formula R 1 -T-, and each of the other three independently represents a hydrogen atom or a group selected from the following substituent group γ-1;

R 1 represents a C 6-10 aryl group or a C 6-10 aryl group substituted with one to five groups selected from the following substituent group α-1, wherein, when the number of the substituents is two or more, each of the substituents may be the same or different;

T represents a single bond or —O—;

G represents an oxygen atom;

R 2 represents a C 6-10 aryl group or a C 6-10 aryl group substituted with one to five groups selected from the following substituent group β-1, wherein, when the number of the substituents is two or more, each of the substituents may be the same or different;

X represents —CH═CH—, or —CH 2 CH 2 —;

Y′ represents a carboxy group; and

M represents a single bond, or the formula —Z 2 —O— wherein, the bond at the left-hand end binds to G, and the bond at the right-hand end binds to R 2 in each of the formulas; and

Z 2 represents a C 1-9 straight chain alkylene group; provided that:

when R 33 is the formula R 1 -T-; each of R 31 , R 32 and R 34 is a hydrogen atom; R 1 is a C 6-10 aryl group or a C 6-10 aryl group substituted with a group or groups selected from a halogen atom, a nitro group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a C 1-6 alkylsulfanyl group, an amino group and a C 1-6 alkylenedioxy group; R 2 is a C 6-10 aryl group or a C 6-10 aryl group substituted with a group or groups selected from a halogen atom, a nitro group, a C 1-6 alkroup, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a phenyl group and a carboxy group; and M is a single bond; then T represents is —O—;

[substituent group α-1]

a halogen atom, a cyano group, a nitro group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a C 1-6 alkylsulfanyl group, an amino group and a C 1-6 alkylenedioxy group;

[substituent group β-1]

a halogen atom, a nitro group, a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, a halogenated C 1-6 alkoxy group, a C 1-6 alkylsulfanyl group, a phenyl group and a carboxy group;

[substituent group γ-1]

a halogen atom, a C 1-6 alkyl group and a C 1-6 alkoxy group.

2. A medicament comprising the compound according to claim 1 or a pharmacologically acceptable salt thereof.

3. The compound or the salt thereof according to claim 1 , wherein one of R 31 , R 32 , R 33 and R 34 is the formula R 1 -T-, and each of the other three is a hydrogen atom.

4. The compound or the salt thereof according to claim 3 , wherein R 32 is the formula R 1 -T-.

5. The compound or the salt thereof according to claim 1 , wherein R 1 is a phenyl group substituted with one or two groups selected from the substituent group α-1.

6. The compound or the salt thereof according to claim 1 , wherein R 1 is a phenyl group substituted with a group selected from a C 1-6 alkyl group, a C 1-6 alkoxy group, and a halogenated C 1-6 alkoxy group.

7. The compound or the salt thereof according to claim 1 , wherein R 1 is a phenyl group substituted with a halogenated C 1-6 alkoxy group.

8. The compound or the salt thereof according to claim 1 , wherein R 1 is a group selected from the group consisting of:

9. The compound or the salt thereof according to claim 1 , wherein T is a single bond.

10. The compound or the salt thereof according to claim 1 , wherein R 2 is a phenyl group substituted with one or two groups selected from the substituent group β-1.

11. The compound or the salt thereof according to claim 1 , wherein R 2 is a phenyl group substituted with a group selected from a C 1-6 alkyl group, a halogenated C 1-6 alkyl group, a C 1-6 alkoxy group, and a halogenated C 1-6 alkoxy group.

12. The compound or the salt thereof according to claim 1 , wherein R 2 is a group selected from the group consisting of:

13. The compound or the salt thereof according to claim 1 , wherein X is —CH 2 CH 2 —.

14. The compound or the salt thereof according to claim 1 , wherein M is a single bond.

15. The compound or the salt thereof according to claim 1 , wherein the compound is selected from the group consisting of:

16. The compound or the salt thereof according to claim 15 , wherein the compound is selected from the group consisting of:

17. The compound or salt thereof according to claim 15 , wherein, the compound is selected from the group consisting of:

18. The compound or the salt thereof according to claim 15 , wherein the compound is selected from the group consisting of:

19. The compound or salt thereof according to claim 15 , wherein the compound is selected from the group consisting of:

20. The compound or the salt thereof according to claim 15 , wherein, the compound is selected from the group consisting of:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2009
From: YAMAGUCHI, YOUICHI; YANASE, TAKESHI; MUTO, SUSUMU; ITAI, AKIKO
To: INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC.
Reel/Frame 023098/0732 →
Continuity (2)
Provisional Application 61044108 · Apr 11, 2008
Related Publication 20090312315A1 · Dec 17, 2009